Gastric Cancer
Conditions
Interventions
Test Group:chemotherapy+Banxiaxiexin decoction
Control Group:chemotherapy
Sponsors
Shuguang Hospital, Shanghai University of Traditional Chinese Medicine
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1. Age ranges from 18 to 75 years (including 18 and 75 years), and gender is not limited. 2. Subjects need to meet one of the following two conditions: (1) Pathological cytology and/or histology confirmed palliative or neoadjuvant radiotherapy and chemotherapy for advanced gastric cancer or esophagogastric junction cancer, and at least one measurable lesion displayed by imaging examination (PET-CT, CT, MRI, bone scan, gastroscopy); (2) Adjuvant chemotherapy for gastric cancer or esophagogastric junction cancer confirmed by pathological cytology and/or histology: ? T2N0M0 with high risk factors (age < 40 years old; high or low histological grade; infiltration of nerve bundles or blood vessels or lymphatic vessels); ? T3-4 NanyM0; ? TanyN+M0; ? R0 excision. 3. The general condition of patients was good, ECOG (0-2). 4. TCM syndromes belong to the miscellaneous syndromes of cold and heat. 5. Blood routine, heart, liver and kidney function, cardiac ultrasonography, coagulation function, electrocardiogram and other indicators are in line with the treatment indications. 6. Voluntarily accept the observation of this research plan, with good compliance, clear thinking, clear expression and normal language and sensory response. 7. Subjects were able to understand the study and sign informed consent and were willing to follow up.
Exclusion criteria
Exclusion criteria: 1. Severe diseases such as heart, liver, kidney and hematopoietic system, pregnancy or lactationand uncontrollable psychosis. 2. Symptomatic brain metastases, with complications associated with brain metastasis and cognitive impairment. 3. Patients with dysphagia, complete or incomplete gastrointestinal obstruction, active gastrointestinal bleeding, perforation and other contraindications to the use of chemotherapeutic drugs. 4. Allergies to this drug are known. 5. Active tuberculosis and other serious infectious diseases. 6. Taking part in or taking part in clinical trials of other drugs within 4 weeks. 7. Have a history of organ transplantation.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Progression free survival;Disease free survival; | — |
Secondary
| Measure | Time frame |
|---|---|
| Overall survival;TCM syndromes points;Immune function;Quality of life;Safety;Intestinal flora;metabonomics; | — |
Countries
China
Contacts
Public ContactLiu Ningning
Department of Medical Oncology, Shuguang Hospital, Shanghai University of Traditional Chinese Medicine
Outcome results
None listed